Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
1,074,494
-
Share change
-
-87,168
-
Total reported value
-
$3,867,000
-
Price per share
-
$3.60
-
Number of holders
-
16
-
Value change
-
-$337,181
-
Number of buys
-
6
-
Number of sells
-
6
Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q2 2022
As of 30 Jun 2022,
Gain Therapeutics, Inc. - COM (GANX) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,074,494 shares.
The largest 10 holders included
GREENLIGHT CAPITAL INC, Telemetry Investments, L.L.C., CM Management, LLC, PRELUDE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, ROYAL BANK OF CANADA, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., and ADVISOR GROUP HOLDINGS, INC..
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.